BACKGROUND: A competitive Luminex Immunoassay (cLIA) has been developed to measure neutralizing antibodies against human papillomavirus (HPV) types 6, 11, 16 and 18. METHODS: In a cohort of 974 women from the Guanacaste Natural History Study, we studied the relationship of baseline cLIA and virus-like particle (VLP) enzyme-linked immunosorbent assay (ELISA) (HPV16 and HPV18 only) seropositivity to measures of HPV exposure, HPV DNA positivity, number of sexual partners, cytology findings, and age. We then studied immunity against subsequent infection with HPV6, 11, 16, 18 and related types over a 7-year period. RESULTS: cLIA seroprevalence varied with previous exposure; the prevalence of cLIA results positive for HPV16 and HPV18 was lower than the prevalence of positive VLP ELISA responses. cLIA and VLP ELISA positivity predicted protection from subsequent infections with concordant types. The combined odds ratio for HPV16 and HPV18 cLIA positivity was 0.41 (95% confidence interval [CI], 0.21-0.80), and the combined odds ratio for the HPV16 and HPV18 VLP ELISA positivity was 0.65 (95% CI, 0.46-0.93). Of individual types, statistical significance was only reached for HPV16 cLIA positivity (odds ratio, 0.44; 95% CI, 0.15-0.94). CONCLUSIONS: Both assays showed an association between positive results and significant protection from subsequent infections for HPV16 and HPV18 combined. cLIA seroprevalence was lower than VLP ELISA, suggesting that the assay detects a subset of antibodies following natural infection that are specifically linked to immunity against subsequent HPV infection.
BACKGROUND: A competitive Luminex Immunoassay (cLIA) has been developed to measure neutralizing antibodies against human papillomavirus (HPV) types 6, 11, 16 and 18. METHODS: In a cohort of 974 women from the Guanacaste Natural History Study, we studied the relationship of baseline cLIA and virus-like particle (VLP) enzyme-linked immunosorbent assay (ELISA) (HPV16 and HPV18 only) seropositivity to measures of HPV exposure, HPV DNA positivity, number of sexual partners, cytology findings, and age. We then studied immunity against subsequent infection with HPV6, 11, 16, 18 and related types over a 7-year period. RESULTS: cLIA seroprevalence varied with previous exposure; the prevalence of cLIA results positive for HPV16 and HPV18 was lower than the prevalence of positive VLP ELISA responses. cLIA and VLP ELISA positivity predicted protection from subsequent infections with concordant types. The combined odds ratio for HPV16 and HPV18 cLIA positivity was 0.41 (95% confidence interval [CI], 0.21-0.80), and the combined odds ratio for the HPV16 and HPV18 VLP ELISA positivity was 0.65 (95% CI, 0.46-0.93). Of individual types, statistical significance was only reached for HPV16 cLIA positivity (odds ratio, 0.44; 95% CI, 0.15-0.94). CONCLUSIONS: Both assays showed an association between positive results and significant protection from subsequent infections for HPV16 and HPV18 combined. cLIA seroprevalence was lower than VLP ELISA, suggesting that the assay detects a subset of antibodies following natural infection that are specifically linked to immunity against subsequent HPV infection.
Authors: R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer Journal: J Virol Date: 1997-08 Impact factor: 5.103
Authors: Marij J P Welters; Pauline van der Logt; Susan J F van den Eeden; Kitty M C Kwappenberg; Jan Wouter Drijfhout; Gert Jan Fleuren; Gemma G Kenter; Cornelis J M Melief; Sjoerd H van der Burg; Rienk Offringa Journal: Int J Cancer Date: 2006-02-15 Impact factor: 7.396
Authors: A C Rodríguez; P E Castle; J S Smith; C Bratti; A Hildesheim; M Schiffman; R Viscidi; R D Burk; R L Ashley; X Castellsagué; R Herrero Journal: Sex Transm Infect Date: 2003-12 Impact factor: 3.519
Authors: Raphael P Viscidi; Mark Schiffman; Allan Hildesheim; Rolando Herrero; Philip E Castle; Maria C Bratti; Ana Cecilia Rodriguez; Mark E Sherman; Sophia Wang; Barbara Clayman; Robert D Burk Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-02 Impact factor: 4.254
Authors: Diana V Pastrana; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Philip E Castle; Peter C FitzGerald; Susanne Krüger Kjaer; Douglas R Lowy; John T Schiller Journal: Virology Date: 2004-04-10 Impact factor: 3.616
Authors: Marij J P Welters; Annemieke de Jong; Susan J F van den Eeden; Jeanette M van der Hulst; Kitty M C Kwappenberg; Sabrin Hassane; Kees L M C Franken; Jan Wouter Drijfhout; Gert Jan Fleuren; Gemma Kenter; Cornelis J M Melief; Rienk Offringa; Sjoerd H van der Burg Journal: Cancer Res Date: 2003-02-01 Impact factor: 12.701
Authors: David Opalka; Charles E Lachman; Stefani A MacMullen; Kathrin U Jansen; Judith F Smith; Narendra Chirmule; Mark T Esser Journal: Clin Diagn Lab Immunol Date: 2003-01
Authors: R B Roden; E M Weissinger; D W Henderson; F Booy; R Kirnbauer; J F Mushinski; D R Lowy; J T Schiller Journal: J Virol Date: 1994-11 Impact factor: 5.103
Authors: S S Wang; M Schiffman; R Herrero; J Carreon; A Hildesheim; A C Rodriguez; M C Bratti; M E Sherman; J Morales; D Guillen; M Alfaro; B Clayman; R D Burk; R P Viscidi Journal: Br J Cancer Date: 2004-10-04 Impact factor: 7.640
Authors: Lauren Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen Journal: J Infect Dis Date: 2014-02-25 Impact factor: 5.226
Authors: Daniel C Beachler; Raphael Viscidi; Elizabeth A Sugar; Howard Minkoff; Howard D Strickler; Ross D Cranston; Dorothy J Wiley; Lisa P Jacobson; Kathleen M Weber; Joseph B Margolick; Susheel Reddy; Maura L Gillison; Gypsyamber D'Souza Journal: Sex Transm Dis Date: 2015-02 Impact factor: 2.830
Authors: Beibei Lu; Raphael P Viscidi; Yougui Wu; Ji-Hyun Lee; Alan G Nyitray; Luisa L Villa; Eduardo Lazcano-Ponce; Roberto J Carvalho da Silva; Maria Luiza Baggio; Manuel Quiterio; Jorge Salmeron; Danelle C Smith; Martha E Abrahamsen; Mary R Papenfuss; Heather G Stockwell; Anna R Giuliano Journal: Cancer Res Date: 2011-11-28 Impact factor: 12.701
Authors: Lauren E Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen Journal: Int J Cancer Date: 2013-05-29 Impact factor: 7.396